---
title: "Oncolytics Biotech Inc. (ONCY.US) — 公司概況"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/ONCY.US/overview.md"
symbol: "ONCY.US"
name: "Oncolytics Biotech Inc."
parent: "https://longbridge.com/zh-HK/quote/ONCY.US.md"
datetime: "2026-04-15T09:32:27.103Z"
locales:
  - [en](https://longbridge.com/en/quote/ONCY.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ONCY.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ONCY.US/overview.md)
---

# Oncolytics Biotech Inc. (ONCY.US) — 公司概況

## 基本資訊

| 項目 | 詳情 |
|------|--------|
| 行業 | 生物技術 |
| 交易所 | US Market |
| 地址 | 322 11th Avenue SW, Suite 804, Calgary, Alberta, Canada |
| 官網 | [oncolyticsbiotech.com](https://oncolyticsbiotech.com) |

## 公司簡介

Oncolytics Biotech Inc.是一家臨床階段的生物制藥公司，專注于腫瘤治療的研究、開發和商業化。該公司開發了 pelareorep，這是一種通過靜脈輸注的免疫治療藥物，用于治療激素受體陽性/人類表皮生長因子 2 陰性晚期和轉移性乳腺癌、轉移性胰腺導管腺癌和肛門癌。它與羅氏控股公司（Roche Holding AG）達成協議，供應其免疫檢查點抑制劑阿特珠單抗（atezolizumab），用于其正在進行的贊助研究。Oncolytics Biotech Inc

## 核心管理層

| 名稱 | 職位 |
|------|-------|
| Jared Kelly | CEO & Director |
| Wayne F. Pisano | Chairman of the Board |
| Kirk J. Look | Chief Financial Officer |
| Thomas C. Heineman | Chief Medical Officer |
| John McAdory | Executive VP of Strategy & Operations |
| Allison Hagerman | Chief Technology Officer |
| Angela Frances Holtham | Independent Director |
| Deborah M. Brown | Independent Director |
| Jonathan M. N. Rigby | Independent Director |

## 主要股東

| 名稱 | 佔比 | 報告日期 |
|------|-------|-------------|
| Bernd Robert Seizinger | 0.49% | 2026-02-12 |
| Wayne F. Pisano | 0.42% | 2026-02-12 |
| Morgan Stanley | 0.37% | 2025-12-31 |
| Sandbox Financial Partners, LLC | 0.34% | 2026-03-31 |
| Kirk J. Look | 0.25% | 2026-02-12 |
| Thomas C. Heineman | 0.24% | 2026-02-12 |
| Marshall Wace LLP | 0.23% | 2025-12-31 |
| Seeds Investor LLC | 0.22% | 2025-12-31 |
| International Assets Investment Management, LLC | 0.18% | 2025-12-31 |
| Angela Frances Holtham | 0.16% | 2026-01-01 |


---

> **免責聲明: 本文僅供參考，不構成任何投資建議。**